Nationales Centrum für Tumorerkrankungen - Heidelb

Heidelberg 69120

0 studies enrolling now · 1 studies all time

What they study most

PD-L1 Negative, Triple Negative Breast Cancer

Studies at this site

• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling